細胞免疫療法市場：按治療方法、來源、適應症、生產方法、最終用戶和地區分類

預計到2026年，細胞免疫療法市場規模將達到88.1億美元，2033年將達238.6億美元。預計從2026年到2033年，該市場將以15.3%的複合年成長率成長。

全球細胞免疫療法市場代表著現代醫學的突破性模式轉移，它利用人體自身的免疫系統來對抗各種疾病，特別是癌症和自體免疫疾病。

這種創新療法透過採集和改造免疫細胞，然後將其重新輸注給患者，從而增強人體自身的防禦機制。細胞免疫療法涵蓋多種治療方法，包括CAR-T細胞療法、腫瘤浸潤淋巴細胞（TIL）療法、自然殺手（NK）細胞療法和樹突狀細胞疫苗，每種療法都有其獨特的作用機制，針對特定的疾病路徑。

隨著Kymriah和Yescarta等CAR-T療法的突破性核准，市場正經歷前所未有的成長。這些療法在治療難治性骨髓惡性腫瘤展現出顯著療效。先進的生產技術，例如自動化細胞處理系統和密封生物反應器，顯著提高了這些個人化療法的擴充性和標準化。

包括CRISPR-Cas9等基因編輯工具、合成生物學平台以及人工智慧（AI）驅動的患者篩選演算法在內的生物技術創新融合，不斷拓展細胞免疫療法的治療可能性。隨著全球醫療體系逐漸認知到這些「活體藥物」的變革潛力，對研究基礎設施、法規結構和報銷政策的大量投資正在加速市場滲透，並提高不同患者群體獲得治療的機會。

市場動態

全球細胞免疫療法市場正經歷強勁成長，這主要得益於多項強勁因素的推動。其中最主要的促進因素是全球癌症發生率的不斷上升，尤其是在骨髓惡性腫瘤，細胞免疫療法已展現出卓越的臨床療效。此外，製藥巨頭、生物技術公司和學術機構在研發方面的巨額投入也大大促進了該市場的發展，加速了下一代細胞工程技術的創新，並將治療應用範圍從腫瘤學拓展至自體免疫疾病、感染疾病和再生醫學等領域。

監管機構為細胞免疫療法設立加速核准途徑、認定突破性治療方法和認定孤兒藥，正在縮短有前景的治療方法上市時間，並刺激持續的投資和研發。

然而，該市場面臨許多限制因素，包括個人化細胞處理相關的極高製造成本、需要專業設施和訓練有素人員的複雜供應鏈物流，以及在維持產品品質和一致性的同時擴大生產規模所面臨的巨大技術挑戰。漫長的生產週期（通常需要數週才能生產出針對特定患者的療法）也帶來了進一步的營運挑戰，並限制了嚴重患者獲得治療的機會。

此外，某些細胞免疫療法相關的嚴重不利事件，例如細胞激素釋放症候群和神經毒性，需要專門的醫療基礎設施和專業知識，這限制了資源不足的醫療機構採用這些療法。儘管存在這些挑戰，但該市場仍蘊藏著巨大的機遇，例如將適應症擴展到固體癌患者群體遠大於目前的血液系統疾病適應症），以及開發現成的同種異體細胞療法（可顯著降低成本和生產複雜性，同時提高全球市場的可及性和擴充性）。

本次調查的主要特點

• 本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數創建了全球細胞免疫療法市場主要公司的概況：公司亮點、產品系列、關鍵亮點、財務表現和策略。
• 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份全球細胞免疫療法市場報告的目標受群眾外包括行業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 透過分析全球細胞免疫療法市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 促進因素
• 抑制因子
• 機會
• 影響分析
• 主要進展
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 產業趨勢

第4章 全球細胞免疫療法市場：依療法類型分類，2021-2033年

• CAR T細胞療法（嵌合體抗原受體T細胞）
• TCR-T細胞療法（T細胞受體T細胞）
• NK細胞療法（自然殺手細胞療法）
• 樹突細胞療法
• 腫瘤浸潤淋巴細胞（TIL）療法
• 基於巨噬細胞的細胞療法
• 其他（新興/新型細胞類型）

第5章 全球細胞免疫療法市場：依來源分類，2021-2033年

• 自體（患者來源細胞）
• 同種異體（供體來源細胞）

第6章 全球細胞免疫療法市場：依適應症分類，2021-2033年

• 癌症
• 感染疾病
• 自體免疫疾病
  • 介紹
  • 市場規模及預測、年增速分析
    • 多發性硬化症
      • 類風濕性關節炎
      • 1型糖尿病
• 其他
  • 介紹
  • 市場規模及預測、年增速分析

第7章 全球細胞免疫療法市場：依生產方法分類，2021-2033年

• 體外細胞增殖
• 生物醫學工程

第8章 全球細胞免疫療法市場：依最終用戶分類，2021-2033年

• 醫院和診所
• 內分泌與肥胖專科治療中心
• 門診手術中心（ASC）
• 家庭醫療保健服務
• 其他（學術和研究機構等）

第9章 全球細胞免疫療法市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第10章 競爭格局

• Novartis AG
• Gilead Sciences Inc（Kite Pharma）
• Bristol Myers Squibb Company
• Johnson and Johnson（Janssen Biotech）
• Cellectis SA
• Adaptimmune Therapeutics plc
• Autolus Therapeutics plc
• Allogene Therapeutics Inc
• Atara Biotherapeutics Inc
• Legend Biotech Corporation
• bluebird bio Inc
• Fate Therapeutics Inc
• ImmunityBio Inc
• Iovance Biotherapeutics Inc
• Poseida Therapeutics Inc

第11章 分析師建議

• 機會分析
• 分析師意見
• Coherent Opportunity Map

第12章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Cellular Immunotherapy Market is estimated to be valued at USD 8.81 Bn in 2026 and is expected to reach USD 23.86 Bn by 2033, growing at a compound annual growth rate (CAGR) of 15.3% from 2026 to 2033.

The global cellular immunotherapy market represents a revolutionary paradigm shift in modern medicine, leveraging the body's own immune system to combat various diseases, particularly cancer and autoimmune disorders.

This innovative therapeutic approach involves extracting, modifying, and reintroducing immune cells back into patients to enhance their natural defense mechanisms. Cellular immunotherapy encompasses diverse treatment modalities including CAR-T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, natural killer (NK) cell therapy, and dendritic cell vaccines, each offering unique mechanisms of action to target specific disease pathways.

The market has witnessed unprecedented growth following breakthrough approvals of CAR-T therapies such as Kymriah and Yescarta, which demonstrated remarkable efficacy in treating refractory hematologic malignancies. Advanced manufacturing technologies, including automated cell processing systems and closed-system bioreactors, have significantly improved the scalability and standardization of these personalized treatments.

The convergence of biotechnology innovations, including gene editing tools like CRISPR-Cas9, synthetic biology platforms, and artificial intelligence-driven patient selection algorithms, continues to expand the therapeutic potential of cellular immunotherapies. As healthcare systems globally recognize the transformative potential of these living medicines, substantial investments in research infrastructure, regulatory frameworks, and reimbursement policies are accelerating market adoption and accessibility across diverse patient populations.

Market Dynamics

The global cellular immunotherapy market experiences robust growth driven by several compelling factors, with the primary driver being the increasing prevalence of cancer worldwide, particularly hematologic malignancies where cellular immunotherapies have demonstrated exceptional clinical outcomes. The market benefits significantly from substantial investments in research and development activities by pharmaceutical giants, biotechnology companies, and academic institutions, fostering innovation in next-generation cell engineering technologies and expanding therapeutic applications beyond oncology into autoimmune diseases, infectious diseases, and regenerative medicine.

Regulatory agencies' establishment of expedited approval pathways, breakthrough therapy designations, and orphan drug status for cellular immunotherapies has accelerated time-to-market for promising treatments, encouraging continued investment and development.

However, the market faces considerable restraints including extremely high manufacturing costs associated with personalized cell processing, complex supply chain logistics requiring specialized facilities and trained personnel, and significant technical challenges in scaling production while maintaining product quality and consistency. Lengthy manufacturing timelines, often requiring weeks to produce patient-specific treatments, pose additional operational challenges and limit treatment accessibility for critically ill patients.

Furthermore, severe adverse events such as cytokine release syndrome and neurotoxicity associated with certain cellular immunotherapies necessitate specialized medical infrastructure and expertise, constraining adoption in healthcare facilities lacking adequate resources. Despite these challenges, the market presents substantial opportunities through expanding applications into solid tumors, which represent a significantly larger patient population than current hematologic indications, and the development of off-the-shelf allogeneic cell therapies that could dramatically reduce costs and manufacturing complexity while improving treatment accessibility and scalability across global markets.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cellular immunotherapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis AG, Gilead Sciences Inc (Kite Pharma), Bristol Myers Squibb Company, Johnson and Johnson (Janssen Biotech), Cellectis S.A., Adaptimmune Therapeutics plc, Autolus Therapeutics plc, Allogene Therapeutics Inc, Atara Biotherapeutics Inc, Legend Biotech Corporation, bluebird bio Inc, Fate Therapeutics Inc, ImmunityBio Inc, Iovance Biotherapeutics Inc, and Poseida Therapeutics Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global cellular immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cellular immunotherapy market

Market Segmentation

• Therapy Type Insights (Revenue, USD Bn, 2021 - 2033)
• CAR T-Cell Therapy (Chimeric Antigen Receptor T-cell)
• TCR-T Cell Therapy (T-Cell Receptor T-cell)
• NK Cell Therapy (Natural Killer cell therapy)
• Dendritic Cell Therapy
• Tumor-Infiltrating Lymphocytes (TIL) Therapy
• Macrophage-Based Cell Therapy
• Others (emerging/novel cell types)
• Source Insights (Revenue, USD Bn, 2021 - 2033)
• Autologous (patient-derived cells)
• Allogeneic (donor-derived cells)
• Indication Insights (Revenue, USD Bn, 2021 - 2033)
• Cancer
• Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma)
• Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)
• Infectious Diseases
• Bacterial Infections (e.g., tuberculosis)
• Autoimmune Disorders
• Multiple Sclerosis
• Rheumatoid Arthritis
• Type 1 Diabetes
• Others
• Manufacturing Modality Insights (Revenue, USD Bn, 2021 - 2033)
• Ex Vivo Cell Expansion
• In Vivo Engineering
• End User Insights (Revenue, USD Bn, 2021 - 2033)
• Hospitals and Clinics
• Specialty Endocrinology and Obesity Centers
• Ambulatory Surgical Centers (ASCs)
• Home Healthcare Services
• Others (Academic and Research Institutes, etc.)
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Novartis AG
• Gilead Sciences Inc (Kite Pharma)
• Bristol Myers Squibb Company
• Johnson and Johnson (Janssen Biotech)
• Cellectis S.A.
• Adaptimmune Therapeutics plc
• Autolus Therapeutics plc
• Allogene Therapeutics Inc
• Atara Biotherapeutics Inc
• Legend Biotech Corporation
• bluebird bio Inc
• Fate Therapeutics Inc
• ImmunityBio Inc
• Iovance Biotherapeutics Inc
• Poseida Therapeutics Inc

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Cellular Immunotherapy Market, By Therapy Type
  • Global Cellular Immunotherapy Market, By Source
  • Global Cellular Immunotherapy Market, By Indication
  • Global Cellular Immunotherapy Market, By Manufacturing Modality
  • Global Cellular Immunotherapy Market, By End User
  • Global Cellular Immunotherapy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Cellular Immunotherapy Market, By Therapy Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• CAR T-Cell Therapy (Chimeric Antigen Receptor T-cell)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• TCR-T Cell Therapy (T-Cell Receptor T-cell)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• NK Cell Therapy (Natural Killer cell therapy)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Dendritic Cell Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Tumor-Infiltrating Lymphocytes (TIL) Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Macrophage-Based Cell Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others (emerging/novel cell types)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Cellular Immunotherapy Market, By Source, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Autologous (patient-derived cells)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Allogeneic (donor-derived cells)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Cellular Immunotherapy Market, By Indication, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma)
      • Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)
• Infectious Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Bacterial Infections (e.g., tuberculosis)
• Autoimmune Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Multiple Sclerosis
      • Rheumatoid Arthritis
      • Type 1 Diabetes
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Cellular Immunotherapy Market, By Manufacturing Modality, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Ex Vivo Cell Expansion
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• In Vivo Engineering
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Cellular Immunotherapy Market, By End User, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospitals and Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Specialty Endocrinology and Obesity Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Ambulatory Surgical Centers (ASCs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Home Healthcare Services
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others (Academic and Research Institutes, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Cellular Immunotherapy Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Manufacturing Modality, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Manufacturing Modality, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Manufacturing Modality, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Manufacturing Modality, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Manufacturing Modality, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Manufacturing Modality, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive landscape

• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gilead Sciences Inc (Kite Pharma)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson and Johnson (Janssen Biotech)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cellectis S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Adaptimmune Therapeutics plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Autolus Therapeutics plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Allogene Therapeutics Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Atara Biotherapeutics Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Legend Biotech Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• bluebird bio Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Fate Therapeutics Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• ImmunityBio Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Iovance Biotherapeutics Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Poseida Therapeutics Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us